Rajeev Karwal, Man Behind Made-In-India Robots Dies Of COVID-19

New Delhi: Founder Chairman of Milagrow Robots and the man behind Made-in-India robots, Rajeev Karwal, died of COVID 19 on Wednesday morning after being on ventilator support for almost a week.

Milagrow’s robots were of significance during COVID as hospitals had started using Milagrow’s humanoid to help doctors. The first hospital humanoid ELF was deployed in the advanced COVID-19 ward at AIIMS, Delhi to shield doctors and healthcare care workers from the virus, India Today reported.

In his recent interviews, Karwal had spoken about Milagrow’s growth, which did well in the backdrop of the pandemic as the demand for robots increased for house help as well as for educational purposes. He had said that robots replaced 80 per cent of the labour formerly employed tasks like cleaning windows, and swimming pools. He had also noted that Milagorw surpassed its 2019 turnover in the first four months of 2020, with sales in the first half of August equalling half its sales in the previous four months, the report added.

Karwal was known for his contribution to the Indian electronics and technology space. He was known for his brand-building efforts at LG, ONIDA, Philips and Electrolux, where he became part of the senior management. He was known for transforming LG Corp as their VP of Sales and Marketing. He also worked as the president and CEO of Reliance Digital for a year before he founded Milagrow in 2007. Milagrow was set up in 2007 for management consultancy and by 2012 the company transitioned to making robots for residential and industrial use.

In 2004, Karwal debuted in the Economic Times India’s Most Powerful CEOs list and was featured in Business Today’s Top 25 Hot Young Rising Stars of India Inc in 2002. In 2001 he won India’s Young Manager Trophy, awarded by the Confederation of Indian Industry. In 2000 he was voted one of the Stars of the Millennium by Business India. He also won multiple Philips International Leadership Grand Prix Championships.

Comments are closed.